quinazolines has been researched along with Ventricular Dysfunction, Left in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Achenbach, H; Egyed, M; Gercheva, L; Gotic, M; Kvasnicka, HM; Warzocha, K; Wu, J | 1 |
Chang, MJ; Choi, HD | 1 |
Byrne, J; Ewer, MS; Koehler, M; Perez, EA; Preston, AJ; Rappold, E | 1 |
Greufe, S; Hayward, R; Hydock, DS; Schneider, CM; Wonders, KY | 1 |
Fowler, MB; Telli, ML; Witteles, RM | 1 |
Criscitiello, C; de Azambuja, E; de Castro, G; Diaz, M; La Gerche, A; Metzger-Filho, O; Piccart-Gebhart, MJ; Saini, KS | 1 |
Eijsman, L; van Wezel, HB; van Zwieten, PA; Visser, CA; Vroom, MB | 1 |
3 review(s) available for quinazolines and Ventricular Dysfunction, Left
Article | Year |
---|---|
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; ErbB Receptors; Female; Heart; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Cardiac Imaging Techniques; Cardiotoxins; Clinical Trials as Topic; Drug Monitoring; Humans; Lapatinib; Neoplasms; Outcome and Process Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Trastuzumab; Ventricular Dysfunction, Left | 2011 |
Targeted therapies in breast cancer: are heart and vessels also being targeted?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Heart Failure; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab; Ventricular Dysfunction, Left | 2012 |
2 trial(s) available for quinazolines and Ventricular Dysfunction, Left
Article | Year |
---|---|
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Topics: Adolescent; Adult; Aged; Biopsy; Blood Platelets; Bone Marrow Examination; Echocardiography; Europe; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Count; Quinazolines; Stroke Volume; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult | 2021 |
Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Aged; Anesthesia, General; beta-Cyclodextrins; Blood Pressure; Cardiac Output; Cardiotonic Agents; Coronary Artery Bypass; Cyclodextrins; Echocardiography, Transesophageal; Female; Half-Life; Heart Rate; Hemodynamics; Humans; Imidazoles; Infusions, Intravenous; Male; Phosphodiesterase Inhibitors; Premedication; Prospective Studies; Pulmonary Wedge Pressure; Quinazolines; Safety; Solvents; Ventricular Dysfunction, Left | 1995 |
2 other study(ies) available for quinazolines and Ventricular Dysfunction, Left
Article | Year |
---|---|
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stroke Volume; Ventricular Dysfunction, Left | 2008 |
Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974.
Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Caspase 3; Caspase 8; Doxorubicin; Exercise Therapy; Female; Heart; Heart Ventricles; Lipid Peroxidation; Malondialdehyde; Oxidative Stress; Quinazolines; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Pressure | 2009 |